Trial reportCell reports. Medicine2021
Protein/AS01
Open access · goldAbstract readClinical Trial
In one paragraph
Trial report in Cell reports. Medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed
3.6field-weighted citation impact, top 6% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 60 citations in OpenAlex.
- R21/Matrix-M malaria vaccine drives diverse immune responses in pre-exposed adults: insights from a phase IIb controlled human malaria infection trial.Frontiers in immunology · 2025Trial
- Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV.JCI insight · 2022Trial
- B and T cell responses to pre-erythrocytic R21/Matrix-M and blood-stage RH5.1/Matrix-M malaria vaccines in endemic settings.Frontiers in immunology · 2026Article
- Tfh2 and a subset of Tfh1 cells associate with antibody-mediated immunity to malaria.JCI insight · 2025Article
- Prediction and characterisation of the human B cell response to a heterologous two-dose Ebola vaccine.Nature communications · 2025Article
- PfRH5 vaccine; from the bench to the vial.NPJ vaccines · 2025Review
- The saponin monophosphoryl lipid A nanoparticle adjuvant induces dose-dependent HIV vaccine responses in nonhuman primates.The Journal of clinical investigation · 2025Article
- Review
- Human axillary lymph node T follicular helper (Tfh) and Precursor-Tfh cells exhibit functional flexibility following seasonal influenza vaccination.Clinical & translational immunology · 2025Article
- Vaccine-induced responses to R21/Matrix-M - an analysis of samples from a phase 1b age de-escalation, dose-escalation trial.Frontiers in immunology · 2025Article
- Heterogeneity of the human immune response to malaria infection and vaccination driven by latent cytomegalovirus infection.EBioMedicine · 2024Article
- Vaccine-induced human monoclonal antibodies to PfRH5 show broadly neutralizing activity against P. falciparum clinical isolates.NPJ vaccines · 2024Article
- Activation-Induced Marker Assay to Identify and Isolate HCV-Specific T Cells for Single-Cell RNA-Seq Analysis.Viruses · 2024Article
- Blood-stage malaria vaccine candidate RH5.1/Matrix-M in healthy Tanzanian adults and children; an open-label, non-randomised, first-in-human, single-centre, phase 1b trial.The Lancet. Infectious diseases · 2024Article
- Article
- Help me help you: emerging concepts in T follicular helper cell differentiation, identity, and function.Current opinion in immunology · 2024Review
- Review
- Challenges in developing personalized neoantigen cancer vaccines.Nature reviews. Immunology · 2024Review
- MVA-based SARS-CoV-2 vaccine candidates encoding different spike protein conformations induce distinct early transcriptional responses which may impact subsequent adaptive immunity.Frontiers in immunology · 2024Article
- Role of circulating T follicular helper subsets following Ty21a immunization and oral challenge with wild typeFrontiers in immunology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 4 institutions in 2 countries.
Carolyn M NielsenJenner Institute, University of Oxford, Oxford, UK.
Ane OgbeNuffield Department of Clinical Medicine, University of Oxford, Oxford, UK.
Isabela Pedroza-PachecoNuffield Department of Clinical Medicine, University of Oxford, Oxford, UK.
Susanne E DoelemanJenner Institute, University of Oxford, Oxford, UK.
Yue ChenHuman Vaccine Institute, Duke University School of Medicine, Duke University, Durham, NC, USA.
Sarah E SilkJenner Institute, University of Oxford, Oxford, UK.
Jordan R BarrettJenner Institute, University of Oxford, Oxford, UK.
Sean C EliasJenner Institute, University of Oxford, Oxford, UK.
Kazutoyo MiuraLaboratory of Malaria and Vector Research, NIAID/NIH, Rockville, MD, USA.
Ababacar DioufLaboratory of Malaria and Vector Research, NIAID/NIH, Rockville, MD, USA.
Martino BardelliJenner Institute, University of Oxford, Oxford, UK.
Rebecca A DabbsJenner Institute, University of Oxford, Oxford, UK.
Lea BarfodJenner Institute, University of Oxford, Oxford, UK.
Carole A LongLaboratory of Malaria and Vector Research, NIAID/NIH, Rockville, MD, USA.
Barton F HaynesHuman Vaccine Institute, Duke University School of Medicine, Duke University, Durham, NC, USA.
Ruth O PayneJenner Institute, University of Oxford, Oxford, UK.
Angela M MinassianJenner Institute, University of Oxford, Oxford, UK.
Todd BradleyHuman Vaccine Institute, Duke University School of Medicine, Duke University, Durham, NC, USA.
Simon J DraperJenner Institute, University of Oxford, Oxford, UK.
Persephone BorrowNuffield Department of Clinical Medicine, University of Oxford, Oxford, UK.
University of Oxford · GBJenner Institute · GBDuke University · USVector Oncology (United States) · US
Funding
Nonhuman primate studies for development of a prototype HIV vaccine that induces broadly neutralizing antibodiesUM1AI144371 · NIAID · DUKE UNIVERSITY · PI HAYNES, BARTON F. · 2019 to 2025
$190.4MHost Immune Responses to Antigens of Malaria ParasitesZIAAI001020 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI LONG, CAROLE · 2009 to 2025
$13.6MNatural killer cell regulation of the germinal center HIV neutralizing antibody responseR01AI147778 · NIAID · CHILDREN'S MERCY HOSP (KANSAS CITY, MO) · PI BRADLEY, TODD CHRISTOPHER · 2020 to 2024
$3.6MGENE THERAPY FOR IMMUNE DEFICIENCIESZ01AI000645 · NIAID · NIAID EXTRAMURAL ACTIVITIES · PI DE RAVIN, SUK · 1992 to 2008
$873kIntramural NIH HHS Z01 AI000645Medical Research Council MR/K012037/1Medical Research Council MR/K025554/1NIAID NIH HHS R01 AI147778NIAID NIH HHS UM1 AI144371Wellcome Trust 209200/Z/17/Z
Abstract
Interactions between B cells and CD4
Indexed as
AdenoviridaeAdolescentAdultAntibodies, ProtozoanB-LymphocytesCarrier ProteinsFemaleGene Expression ProfilingGene Expression RegulationGenetic VectorsHumansImmunity, HumoralImmunogenicity, VaccineInterferon-gammaInterleukin-5Lipid AAntibodies, ProtozoanAS01B adjuvantCarrier ProteinsCXCR5 protein, humanIFNG protein, humanIL5 protein, humanInterferon-gammaInterleukin-5Lipid AMalaria VaccinesReceptors, CXCR5RH5 protein, Plasmodium falciparumSaponinsVaccines, Subunitadaptive immunityantibodyAS01clinical trialsheterologous viral vectorsmalariaTfh cellsT follicular helper cellsTh1Th2vaccines
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.